secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002679
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen doses first patient in Phase 2 CONNECT1-EDO51 trial for Duchenne muscular dystrophy
--------------------------------------------------------------------------------

- First patient dosed in open-label, multiple ascending dose Phase 2 trial of PGN-EDO51 in DMD patients amenable to exon 51 skipping.
- Trial enrolls ~10 male patients aged >=8 years; starting dose 5 mg/kg escalating to 10 mg/kg pending safety.
- Preliminary data from the 5 mg/kg cohort expected mid-2024: safety, exon skipping, and dystrophin production.
- Phase 1 healthy volunteers showed peak exon 51 skipping of 3.8% after single 10 mg/kg dose; 100% had skipping.
- PGN-EDO51 was generally well-tolerated through 15 mg/kg in Phase 1; trial ID NCT06079736.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024002679/0000950170-24-002679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024002679/pepg-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer